Siltuximab, an anti-IL6 monoclonal antibody drug used in clinic, was shown to be effective in reducing hepcidin expression in patients with Castleman’s disease (CD) and in improving their anemia (van Rhee et al., 2010). This evidence concerns the gene IL6 and anemia.